Winston Tan

TL;DR: Durvalumab demonstrated a manageable safety profile and evidence of meaningful clinical activity in PD-L1-positive patients with UBC, many of whom were heavily pretreated.

TL;DR: Blood-based small RNAs circulating in blood could be used to predict clinical outcomes in late-stage prostate cancer patients and plasma exosomal miRNAs miR-1290 and -375 are promising prognostic biomarkers for CRPC patients are identified.

TL;DR: The ASCO Endorsement Panel determined that the recommendations from the Active Surveillance for the Management of Localized Prostate Cancer guideline, published in May 2015, are clear, thorough, and based upon the most relevant scientific evidence.

TL;DR: Dietary counseling may be offered with the goals of providing patients and caregivers with advice for the management of cachexia, but evidence remains limited and no specific pharmacological intervention can be recommended as the standard of care.

TL;DR: Increased SCD1 expression supports ccRCC viability and therefore it is proposed as a novel molecular target for therapy either independently or in combination with an mTOR inhibitor for patients whose disease cannot be remedied with surgical intervention, such as in cases of advanced or metastatic disease.